Interestingly, various imaging modalities have been utilised to assess tumour response, such as multiparametric MRI (mpMRI) [56], contrast-enhanced ultrasound (CEUS) [57], and prostate-specific membrane antigen (PSMA) positron emission tomography—CT (PET-CT) [58]. This evidence concerns the gene FOLH1 and neoplasm.